Testing effectiveness (Phase 2)UnknownNCT04688983What this trial is testingStudy in Adult Ph-positive ALLWho this might be right forAcute Lymphoblastic Leukemia, Adult Cardiff University 180
Testing effectiveness (Phase 2)Study completedNCT02523976What this trial is testingDasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaWho this might be right forAcute,Leukemia, Lymphoid Institute of Hematology & Blood Diseases Hospital, China 30
Testing effectiveness (Phase 2)UnknownNCT00008307What this trial is testingCombination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic DisordersWho this might be right forLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more Herbert Irving Comprehensive Cancer Center 52
Testing effectiveness (Phase 2)Study completedNCT02067143What this trial is testingMRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted MethotrexateWho this might be right forUntreated Philadelphia Positive Acute Lymphoblastic LeukemiaDe NovoSecondary+1 more Gruppo Italiano Malattie EMatologiche dell'Adulto 204
Large-scale testing (Phase 3)Study completedNCT01511289What this trial is testingRadotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsWho this might be right forLeukemiaLeukemia, MyeloidLeukemia, Myelogenous, Chronic, BCR-ABL Positive+3 more Il-Yang Pharm. Co., Ltd. 242
Testing effectiveness (Phase 2)Study completedNCT00119340What this trial is testingFludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous LeukemiaWho this might be right forLeukemia Fred Hutchinson Cancer Center 75
Early research (Phase 1)Study completedNCT00807677What this trial is testingDose Escalation Study of TAK-901 in Subjects With Advanced Hematologic MalignanciesWho this might be right forAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous Leukemia+9 more Millennium Pharmaceuticals, Inc. 31
Testing effectiveness (Phase 2)Study completedNCT02484430What this trial is testingSapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic LeukemiaWho this might be right forB Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative+3 more National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Study completedNCT00006053What this trial is testingSTI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaWho this might be right forLeukemia Novartis
Testing effectiveness (Phase 2)Study completedNCT01207440What this trial is testingPonatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)Who this might be right forChronic Myeloid LeukemiaPh+ Acute Lymphoblastic Leukemia Ariad Pharmaceuticals 449
Not applicableLooking for participantsNCT07684131What this trial is testingEWALL-PH OBSERVARTORY 2022Who this might be right forAcute Lymphoblastic Leukemia Versailles Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT01746836What this trial is testingPonatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibWho this might be right forChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00384228What this trial is testingA Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALLWho this might be right forChronic Myelogenous LeukemiaAcute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) Novartis Pharmaceuticals 42
Early research (Phase 1)Study completedNCT01460498What this trial is testingAzacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)Who this might be right forLeukemia M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Looking for participantsNCT03263572What this trial is testingBlinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaWho this might be right forAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaBCR-ABL1 Fusion Protein Expression+5 more M.D. Anderson Cancer Center 90
Testing effectiveness (Phase 2)Study completedNCT01427881What this trial is testingCyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)+65 more Fred Hutchinson Cancer Center 43
Early research (Phase 1)Looking for participantsNCT06287528What this trial is testing19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)Who this might be right forPhiladelphia-Negative ALLPhiladelphia-Positive ALLRelapsed ALL, Adult+3 more Memorial Sloan Kettering Cancer Center 18
Not applicableNo Longer AvailableNCT04559555What this trial is testingMAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaWho this might be right forAcute Lymphoblastic Leukemia (ALL) Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT00053248What this trial is testingArsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaWho this might be right forLeukemia OHSU Knight Cancer Institute 16
Testing effectiveness (Phase 2)Study completedNCT00244829What this trial is testingImatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive LeukemiaWho this might be right forLeukemia Fred Hutchinson Cancer Center